Related Experiment Video
Updated: May 2, 2026
04:47
Author Spotlight: Evaluating Traditional Chinese Therapy for Ankylosing Spondylitis in Mice
Published on: October 27, 2023
2.2K
Psoriatic arthritis: recent progress in pathophysiology and drug development
Arthritis Research & Therapy
|March 11, 2014
Summary
Psoriatic arthritis (PsA) is a common inflammatory condition often preceding joint issues. Advances in understanding its pathogenesis have led to targeted therapies like tumor necrosis factor inhibitors (TNFi).
Area of Science:
- Rheumatology and Immunology
Background:
- Psoriatic arthritis (PsA) is the second most prevalent inflammatory arthropathy.
- It often follows years of psoriasis, with potential associated features like nail disease, dactylitis, enthesitis, spondylitis, or uveitis.
- PsA can manifest as symmetrical polyarthritis or asymmetrical oligoarthritis, with early joint damage being common.
Purpose of the Study:
- To review the pathogenesis of PsA, including genetic and molecular biology insights.
- To discuss current and emerging therapeutic strategies for PsA management.
Main Methods:
- Review of recent advances in understanding PsA pathogenesis.
- Analysis of current therapeutic interventions and novel agents in development.
Main Results:
- Understanding of PsA pathogenesis has significantly advanced, implicating innate and adaptive immune systems.
- Tumor necrosis factor inhibitor (TNFi) agents represent a primary targeted therapy.
- Disease-modifying anti-rheumatic drugs (DMARDs) like methotrexate remain first-line, despite limited trials.
Conclusions:
- PsA is a serious condition requiring effective management.
- Targeted therapies, particularly TNFi agents, show excellent efficacy, especially with methotrexate.
- Several novel agents are under development, offering future treatment possibilities.
Related Concept Videos
01:20The JAK-STAT Signaling Pathway
10.2K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
10.2K
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
880
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
880
01:11Genome-wide Association Studies-GWAS
12.6K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
12.6K
01:29Inflammatory Bowel Disease IV: Pharmacological Management
1.1K
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
1.1K
01:29Pharmacogenomics: Identification of New Drug Targets
121
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
121
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
755
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
755